Navigation Links
Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
Date:12/20/2007

LIBERTY CORNER, N.J., Aug. 10 /PRNewswire/ -- Reliant Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of its common stock. The registration statement contemplates that Reliant will sell newly issued common stock and that certain stockholders may sell a portion of their current holdings of Reliant's common stock.

Goldman, Sachs & Co. and Merrill Lynch & Co. will act as the joint lead managers and joint book-runners for the proposed offering. The public offering will be made only by means of a prospectus which, when available, may be obtained by writing or calling one of the underwriters: Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004, Attention: Prospectus Department (Tel: 212-902-1171) or Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department (Tel: 212-449-1000).

A registration statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Reliant Pharmaceuticals, Inc.

Reliant Pharmaceuticals is a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. Reliant currently markets four cardiovascular products in the United States and focuses on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and
'/>"/>

SOURCE Reliant Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Palatin,Technologies, Inc. (Amex: PTN ) announced today ... PL-3994, a novel, long-acting natriuretic peptide,receptor A (NPRA) ... heart failure (CHF). The Phase I trial was ... 26 healthy volunteers who received the medication or ...
... Cepheid (Nasdaq:,CPHD) will present at Cowen and ... 10:15 a.m. ET at The Boston Marriott Copley ... will provide a corporate overview., The webcast, ... Cepheid,s Web site at http://www.cepheid.com under ...
... March 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... its,registrational bioequivalence clinical study of ANX-530 (vinorelbine,emulsion) will ... American Society,of Clinical Oncology (ASCO) in connection with ... - June 3, 2008 in Chicago, IL. The ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4Cepheid to Present at Cowen and Company's 28th Annual Healthcare Conference 2Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology 2Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology 3
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... brain and, more specifically, how nerve cells form billions of contacts ... scientific mystery. , A team headed by Drs. Robin Hiesinger and ... unraveled a piece of that puzzle by finding a gene that ... work appears today in the journal Neuron. , "We were surprised ...
... virus at Churchill Downs, home of the Kentucky Derby, ... that vaccines containing weakened live viruses, called modified live ... horse herpes than other more widely used vaccines. , ... been in use for decades, has proven to be ...
... study has found that a protein known for its ... of initiating DNA repair. The study, published in the ... targets for treatment of cancer. , Ze'ev Ronai, Ph.D., ... colleagues found that the protein ATF2 ("Activating Transcription Factor-2") ...
Cached Biology News:Live vaccines more effective against horse herpes virus 2Live vaccines more effective against horse herpes virus 3New understanding of DNA repair may pave way to cancer treatments 2
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
... content or with significant secondary structure are ... subjected to PCR result in little or ... be increased by the addition of enhancing ... an effective PCR enhancer for GC-rich templates., ...
...
... EPICENTREs patented MasterAmp™ 10X PCR Enhancer ... and allows improved sensitivity and specificity ... Using MasterAmp PCR Enhancer in PCR ... DNA melting, increases enzyme?s thermal stability, ...
Biology Products: